

CITATION REPORT

List of articles citing

The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability

DOI: 10.1055/s-0038-1653759

Thrombosis and Haemostasis, 1995, 73, 247-251.

Source: <https://exaly.com/paper-pdf/84994687/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
493	Acquired inhibitors. 1996 , 9, 331-54		140
492	Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand. 1997 , 27, 658-64		10
491	Inhibitor development and substitution therapy in a developing country: Turkey. <i>Haemophilia</i> , 1998 , 4, 104-8	3.3	22
490	The natural history of the immune response to exogenous factor VIII in severe haemophilia A. <i>Haemophilia</i> , 1998 , 4, 546-51	3.3	15
489	Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. 1998 , 19, 139-48		68
488	Mechanism and Kinetics of Factor VIII Inactivation: Study With an IgG4 Monoclonal Antibody Derived From a Hemophilia A Patient With Inhibitor. <i>Blood</i> , 1998 , 92, 496-506	2.2	142
487	Diagnostik und Therapiesteuerung bei erworbenen Faktorenhemophilien. Diagnostics and Therapy Monitoring in Patients with Acquired Coagulation Factor Inhibitors. 1999 , 23, 70-79		
486	Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. 1999 , 21, 125-8		16
485	German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. <i>Haemophilia</i> , 1999 , 5, 203-6	3.3	35
484	Inter-laboratory variability of the measurement of low titer factor VIII:C inhibitor in haemophiliacs: improvement by the Nijmegen modification of the Bethesda assay and the use of common lyophilized plasmas. <i>Haemophilia</i> , 1999 , 5, 292-3	3.3	7
483	Spontaneous inhibitors of factor VIII: kinetics of inactivation of human and porcine factor VIII. 1999 , 133, 260-4		20
482	NovoSeven in immune tolerance therapy. <i>Blood Coagulation and Fibrinolysis</i> , 2000 , 11 Suppl 1, S39-44	1	35
481	Spontaneous inhibitors to coagulation factors. 2000 , 22 Suppl 1, 21-5; discussion 30-2		19
480	Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A. <i>Haemophilia</i> , 2000 , 6, 140-9	3.3	16
479	THE DIAGNOSIS and MANAGEMENT OF FACTOR VIII and IX INHIBITORS: A GUIDELINE FROM THE UK HAEMOPHILIA CENTRE DOCTORS ORGANIZATION (UKHCDO). <i>British Journal of Haematology</i> , 2000 , 111, 78-90	4.5	1
478	Inhibition of antithrombin by protein SV-IV normalizes the coagulation of hemophilic blood. 2000 , 391, 1-9		8
477	<i>Blood</i> . 2000 ,		

476	Conceptions and misconceptions in testing for lupus anticoagulants. 2000 , 15, 179-83		26
475	The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. 2000 , 99, 21-4		27
474	Recombinant clotting factors: a review of current clinical status. 2000 , 13, 289-98		8
473	Inhibitors in young boys with haemophilia. 2000 , 13, 457-68		21
472	Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. 2001 , 38, 44-51		47
471	Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. 2001 , 38, 52-9		53
470	Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. <i>Blood</i> , 2001 , 98, 13-9	2.2	119
469	Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data. <i>British Journal of Haematology</i> , 2001 , 112, 1062-70	4.5	21
468	Classification of the kinetics of factor VIII inhibitors in haemophilia A: plasma dilution studies are more discriminatory than time-course studies. <i>British Journal of Haematology</i> , 2001 , 114, 861-7	4.5	14
467	Development of inhibitors in patients with haemophilia from India. <i>Haemophilia</i> , 2001 , 7, 273-8	3.3	37
466	Detection of all anti-factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assay. <i>Haemophilia</i> , 2001 , 7, 26-32	3.3	
465	Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. <i>Haemophilia</i> , 2001 , 7, 33-38	3.3	2
464	Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay. <i>Haemophilia</i> , 2001 , 7, 13-19	3.3	1
463	Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A. <i>Haemophilia</i> , 2001 , 7, 364-368	3.3	
462	Postpartum inhibitor to factor VIII: treatment with high-dose immunoglobulin and dexamethasone. <i>Haemophilia</i> , 2001 , 7, 422-427	3.3	1
461	Acquired hemophilia. 2001 , 5, 389-404; quiz following 431		115
460	Acquired factor VII deficiency in hematopoietic stem cell transplant recipients. 2002 , 29, 403-8		23
459	Autoantibodies to factor VIII. 2002 , 1, 105-10		12

458	Acquired hemophilia: a single-center survey with emphasis on immunotherapy and treatment-related side-effects. 2002 , 69, 158-64		19
457	Laboratory aspects of haemophilia therapy. <i>Haemophilia</i> , 2002 , 8, 244-9	3.3	7
456	Pathophysiology of inhibitors to factor VIII in patients with haemophilia A. <i>Haemophilia</i> , 2002 , 8, 273-9	3.3	21
455	Inhibitors: resolving diagnostic and therapeutic dilemmas. <i>Haemophilia</i> , 2002 , 8, 280-7	3.3	107
454	Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A. <i>Haemophilia</i> , 2002 , 8, 644-8	3.3	19
453	First-time development of FVIII inhibitor in haemophilia patients during the postoperative period. <i>Haemophilia</i> , 2002 , 8, 776-80	3.3	32
452	The concept of idiotypic vaccination against factor VIII inhibitors in haemophilia A. <i>Haemophilia</i> , 2002 , 8 Suppl 2, 55-9	3.3	0
451	Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618-->Ser mutation responsive to immune tolerance induction and cyclophosphamide. <i>British Journal of Haematology</i> , 2002 , 117, 136-40	4.5	22
450	Molecular characterization of the immune response to factor VIII. 2002 , 83 Suppl 1, 403-8		14
449	Treatment of patients with haemophilia and inhibitory antibodies. 2003 , 70, 655-9		3
448	Optimization of storage conditions for diluted working solutions of porcine factor VIII and performance of the Bethesda assay for the determination of antiporcine FVIII inhibitor titres. <i>Haemophilia</i> , 2003 , 9, 104-9	3.3	0
447	The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. <i>Haemophilia</i> , 2003 , 9, 38-49	3.3	142
446	Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. <i>Haemophilia</i> , 2003 , 9, 567-72	3.3	40
445	Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 2548-53	15.4	34
444	Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. <i>British Journal of Haematology</i> , 2003 , 121, 21-35	4.5	309
443	Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. <i>Blood</i> , 2003 , 102, 949-52	2.2	49
442	Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. <i>Blood</i> , 2003 , 102, 2038-45	2.2	182
441	Immune tolerance therapy in patients with acquired hemophilia. 2004 , 9, 245-57		8

440	Prophylactic effect of recombinant factor VIIa in factor VII deficient patients. <i>British Journal of Haematology</i> , 2004 , 125, 494-9	4.5	35
439	Inhibitors in congenital coagulation disorders. <i>British Journal of Haematology</i> , 2004 , 127, 379-91	4.5	106
438	Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. <i>Haemophilia</i> , 2004 , 10, 428-37	3.3	132
437	Surgery in haemophilic patients with inhibitor: 20 years of experience. <i>Haemophilia</i> , 2004 , 10 Suppl 2, 30-40	3.3	63
436	Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A. <i>Haemophilia</i> , 2004 , 10, 438-48	3.3	12
435	HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation. <i>Haemophilia</i> , 2004 , 10, 509-14	3.3	19
434	Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1017-9	15.4	34
433	Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1082-95	15.4	104
432	Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 574-83	15.4	66
431	Home management of haemophilia. <i>Haemophilia</i> , 2004 , 10, 118-33	3.3	91
430	Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors. <i>Haemophilia</i> , 2004 , 10, 58-62	3.3	46
429	Acquired isolated factor VII deficiency associated with severe bleeding and successful treatment with recombinant FVIIa (NovoSeven). <i>Blood Coagulation and Fibrinolysis</i> , 2004 , 15, 347-51	1	23
428	Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. <i>Blood Coagulation and Fibrinolysis</i> , 2004 , 15, 109-24	1	65
427	Immune tolerance in children with factors VIII and IX inhibitors: a single centre experience. <i>Haemophilia</i> , 2005 , 11, 340-5	3.3	6
426	Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. <i>Haemophilia</i> , 2005 , 11, 510-5	3.3	80
425	Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. <i>Haemophilia</i> , 2005 , 11, 611-9	3.3	74
424	A simple inhibitor screen is more sensitive than a Bethesda assay in monitoring for the development of inhibitors in haemophilia A and B. <i>British Journal of Haematology</i> , 2005 , 128, 885	4.5	20
423	Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. <i>British Journal of Haematology</i> , 2005 , 130, 422-7	4.5	170

422	Thirteen novel mutations in the factor VIII gene in the Nijmegen haemophilia A patient population. <i>British Journal of Haematology</i> , 2005 , 131, 109-17	4.5	13
421	[Acute airway obstruction in acquired hemophilia A]. 2005 , 53, 462-6		2
420	Characterization of Polyclonal Factor VIII-Inhibitory Antibodies. 2005 , 142-152		
419	Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex. 2005 , 280, 17593-600		39
418	No protective effect of breastfeeding on inhibitor formation in severe hemophilia. 2005 , 22, 575-80		6
417	Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. 2005 , 114, 84-90		24
416	Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. 2005 , 51, 1883-5		36
415	Overview of inhibitors. 2006 , 43, S3-7		40
414	Management of factor VIII inhibitors. 2006 , 19, 51-66		18
413	Investigation of haemostasis. 2006 , 379-440		17
412	Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. <i>Blood</i> , 2006 , 107, 3167-72	2.2	219
411	Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. <i>Blood</i> , 2006 , 108, 3668-73	2.2	54
410	Acquired hemophilia A. 2006 , 11, 119-25		14
409	Blood. 2006 , 1		1
408	Factor V inhibitor: case report. <i>Blood Coagulation and Fibrinolysis</i> , 2006 , 17, 585-7	1	8
407	Risk of inhibitors in haemophilia and the type of factor replacement. <i>Current Opinion in Hematology</i> , 2006 , 13, 316-22	3.3	27
406	[Acquired inhibitor hemophilia]. 2006 , 35, 58-64		1
405	Laboratory issues in bleeding disorders. <i>Haemophilia</i> , 2006 , 12 Suppl 3, 68-75	3.3	43

404	A retrospective postlicensure survey of FEIBA efficacy and safety. <i>Haemophilia</i> , 2006 , 12, 352-62	3.3	104
403	Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. <i>Haemophilia</i> , 2006 , 12, 363-71	3.3	87
402	Pharmacokinetics of recombinant factor VIII (Kogenate-FS [®]) in children and causes of inter-patient pharmacokinetic variability. <i>Haemophilia</i> , 2006 , 12, 40-49	3.3	31
401	Factor VIII pharmacokinetics: impact of low titer non-neutralizing inhibitors and use in determination of successful immune tolerance. <i>Haemophilia</i> , 2006 , 12, 56-60	3.3	3
400	Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. <i>Haemophilia</i> , 2006 , 12, 579-90	3.3	29
399	Inhibitor treatment in haemophilias A and B: inhibitor diagnosis. <i>Haemophilia</i> , 2006 , 12 Suppl 6, 37-41; discussion 41-2	3.3	17
398	Considerations in the management of patients with haemophilia and inhibitors. <i>Haemophilia</i> , 2006 , 12, 2-3	3.3	3
397	The management of acquired haemophilia. <i>Haemophilia</i> , 2006 , 12, 32-36	3.3	20
396	Management of factor VIII inhibitors. <i>International Journal of Hematology</i> , 2006 , 83, 119-25	2.3	26
395	Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. 2006 , 95, 358-71		76
394	Postpartum acquired factor VIII inhibitors. <i>American Journal of Hematology</i> , 2006 , 81, 768-73	7.1	57
393	The role of immunomodulation in the management of factor VIII inhibitors. 2006 , 2006, 421-5		13
392	Acquired factor VIII inhibitors: pathophysiology and treatment. 2006 , 2006, 432-7		108
391	Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. 2006 , 177, 1355-63		43
390	Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. 2007 , 39, 504-11		27
389	von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice. 2007 , 120, 911-9		9
388	O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII. 2007 , 9, E251-9		10
387	Frequency of intron 1 and 22 inversions of Factor VIII gene in Mexican patients with severe hemophilia A. <i>American Journal of Hematology</i> , 2007 , 82, 283-7	7.1	26

386	IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A. <i>Haemophilia</i> , 2007 , 13, 104-5	3-3	20
385	Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. <i>Haemophilia</i> , 2007 , 13, 51-6	3-3	40
384	ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay. <i>Haemophilia</i> , 2007 , 13, 317-22	3-3	44
383	Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. <i>Haemophilia</i> , 2007 , 13, 373-9	3-3	74
382	Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. <i>Haemophilia</i> , 2007 , 13, 697-700	3-3	13
381	Inhibitor development in haemophilia B: an orphan disease in need of attention. <i>British Journal of Haematology</i> , 2007 , 138, 305-15	4-5	196
380	Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2007 , 5, 352-61	15.4	113
379	Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development. <i>Journal of Thrombosis and Haemostasis</i> , 2007 , 5, 1469-76	15.4	36
378	Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. 2008 , 97, 1386-98		42
377	Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 1160-6	15.4	44
376	Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 1319-26	15.4	119
375	Reactivity profile of anti-factor VIII antibodies with designed synthetic peptides mimicking epitopes of the C2 and a1 domains. <i>British Journal of Haematology</i> , 2008 , 141, 708-15	4-5	8
374	IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. <i>British Journal of Haematology</i> , 2008 , 142, 644-52	4-5	70
373	The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. <i>Haemophilia</i> , 2008 , 14, 295-302	3-3	45
372	A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. <i>Haemophilia</i> , 2008 , 14, 281-6	3-3	40
371	Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. <i>Haemophilia</i> , 2008 , 14, 729-35	3-3	32
370	Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab. 2008 , 46, 8-15		18
369	Laboratory, clinical and therapeutic aspects of acquired hemophilia A. 2008 , 395, 14-8		51

368	Monitoring inhibitor patients with the right assays. 2008 , 45, S25-30		17
367	Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study. 2008 , 119, 89-97		5
366	Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. <i>Blood</i> , 2008 , 112, 240-9	2.2	68
365	Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. <i>Blood</i> , 2008 , 112, 2713-21	2.2	83
364	Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience. 2009 , 131, 552-8		55
363	Patterns of acquired bleeding disorders in a tertiary care hospital. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009 , 15, 448-53	3.3	6
362	Inhibitors of factor VIII in black patients with hemophilia. 2009 , 360, 1618-27		160
361	Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. 2009 , 9, 273-83		27
360	Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice. 2009 , 98, 4480-4		23
359	Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives. 2009 , 37, 125-34		8
358	B-cell and T-cell epitopes in anti-factor VIII immune responses. 2009 , 37, 80-95		27
357	Diagnosis and quantification of factor VIII inhibitors. <i>Haemophilia</i> , 2010 , 16, 20-4	3.3	25
356	Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment. <i>Haemophilia</i> , 2009 , 15, 712-7	3.3	6
355	Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. <i>Haemophilia</i> , 2010 , 16, 71-9	3.3	22
354	Kinetics of factor VIII:C inhibitors and treatment response in severe hemophilia A patients. <i>International Journal of Laboratory Hematology</i> , 2009 , 31, 673-82	2.5	5
353	Molecular mechanisms underlying hemophilia A phenotype in seven females. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 976-82	15.4	44
352	Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 930-7	15.4	87
351	Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 2006-2015	15.4	134

350	Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. 2009 , 11, 424-31		37
349	[Acquired von Willebrand syndrome: from diagnosis to treatment]. 2009 , 57, 536-42		1
348	Quantitation of anti-factor VIII antibodies in human plasma. <i>Blood</i> , 2009 , 113, 2587-94	2.2	42
347	Interpreting coagulation assays. <i>Blood Coagulation and Fibrinolysis</i> , 2010 , 21 Suppl 1, S3-6	1	11
346	Standardization of Assays in Hemophilia. 2010 , 254-262		
345	Acquired Inhibitors to Factor VIII. 2010 , 81-87		
344	Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. 2010 , 12, 473-81		23
343	Acquired haemophilia caused by non-haemophilic factor VIII gene variants. 2010 , 89, 607-12		20
342	Diagnosis, laboratory aspects and management of acquired hemophilia A. 2010 , 5, 325-33		30
341	Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A. 2010 , 37, 79-82		20
340	Mild hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 421-32	15.4	76
339	Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 2743-50	15.4	24
338	HLA genotype in patients with acquired haemophilia A. <i>Haemophilia</i> , 2010 , 16, 107-12	3.3	25
337	Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A. <i>Haemophilia</i> , 2010 , 16, e210-5	3.3	11
336	Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia. <i>Haemophilia</i> , 2010 , 16, 662-70	3.3	10
335	Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A. <i>Haemophilia</i> , 2010 , 16, 892-901	3.3	15
334	Haemophilia A and von Willebrand disease. <i>Haemophilia</i> , 2010 , 16 Suppl 5, 79-84	3.3	10
333	Comparative measurement of FVIII inhibitors in hemophilia A patients using ELISA and the Bethesda assay. 2010 , 30, 260-3		2

332	Laboratory Assays in Hemophilia. 2010 , 247-253		3
331	Pharmacotherapy of haemophilia A. 2011 , 11, 1039-53		3
330	Acquired hemophilia A. 2011 , 54, 71-80		12
329	Development of a new modified Bethesda method for coagulation inhibitors: the Osaka modified Bethesda method. <i>Blood Coagulation and Fibrinolysis</i> , 2011 , 22, 185-9	1	7
328	Naturally occurring CD4+ CD25+ cells in modulating immune response to administered coagulation factor VIII in factor VIII-deficient mice. <i>Haemophilia</i> , 2011 , 17, 143-51	3-3	5
327	A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay. <i>Haemophilia</i> , 2011 , 17, 267-74	3-3	9
326	Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients. <i>Haemophilia</i> , 2011 , 17, 275-81	3-3	30
325	Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate [®] : interim report from an ongoing prospective clinical study. <i>Haemophilia</i> , 2011 , 17, 399-406	3-3	17
324	Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans?. <i>Haemophilia</i> , 2011 , 17, 483-9	3-3	26
323	Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE [®]). <i>Haemophilia</i> , 2011 , 17, 407-11	3-3	23
322	Alloantibodies to factor VIII in haemophilia. <i>Haemophilia</i> , 2011 , 17, 636-40	3-3	20
321	Factor VIII inhibitors: a 50-year perspective. <i>Haemophilia</i> , 2011 , 17, 831-8	3-3	23
320	The factor VIII inhibitor assays can be standardized: results of a workshop. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 2003-8	15.4	17
319	Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options. 2011 , 10, 311-6		89
318	Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. <i>Blood</i> , 2011 , 118, 2695-701	2.2	166
317	Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates. 2011 , 18, 246-54		8
316	Laboratory identification of factor inhibitors: an update. 2012 , 44, 293-302		25
315	Role of bone marrow transplantation for correcting hemophilia A in mice. <i>Blood</i> , 2012 , 119, 5532-42	2.2	46

314	Clotting factor concentrate switching and inhibitor development in hemophilia A. <i>Blood</i> , 2012 , 120, 720-722		37
313	Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1581-90	15.4	46
312	Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. 2012 , 119, 1529-37		67
311	PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice. 2012 , 14, 35-42		18
310	Les anticorps anti-FVIII et anti-FIX. 2012 , 2012, 55-62		1
309	[Spontaneous hematoma and hip pain in a 65-year old patient]. 2012 , 53, 1234-9		1
308	Hemophilia management in transfusion medicine. 2012 , 46, 299-307		5
307	F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. <i>Blood</i> , 2012 , 119, 2922-34	2.2	248
306	False-positive results in ELISA-based anti FVIII antibody assay may occur with lupus anticoagulant and phospholipid antibodies. <i>Haemophilia</i> , 2012 , 18, 777-81	3.3	8
305	Clotting Factors and Inhibitors: Assays and Interpretation. 2012 , 435-446		
304	Molecular diagnosis of haemophilia A at Centro Hospitalar de Coimbra in Portugal: study of 103 families--15 new mutations. <i>Haemophilia</i> , 2012 , 18, 129-38	3.3	8
303	Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B. <i>Haemophilia</i> , 2012 , 18, 175-81	3.3	12
302	Risk of inhibitor development in mild haemophilia A increases with age. <i>Haemophilia</i> , 2012 , 18, 263-7	3.3	31
301	Severe haemophilia A patients have reduced numbers of peripheral memory B cells. <i>Haemophilia</i> , 2012 , 18, 437-43	3.3	2
300	F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. <i>Haemophilia</i> , 2012 , 18, 375-82	3.3	90
299	Identification of 123 previously unreported mutations in the F8 gene of Iranian patients with haemophilia A. <i>Haemophilia</i> , 2012 , 18, e340-6	3.3	3
298	The case for wider use of recombinant factor VIII concentrates. 2012 , 83, 11-20		7
297	Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. <i>Haemophilia</i> , 2012 , 18, 798-804	3.3	48

296	Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients. <i>Haemophilia</i> , 2012 , 18, 794-7	3.3	18
295	Mutation spectrum and inhibitor risk in 100 Korean patients with severe haemophilia A. <i>Haemophilia</i> , 2012 , 18, 1008-13	3.3	7
294	A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 359-67	15.4	210
293	Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 706-8	15.4	14
292	Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 622-31	15.4	272
291	Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 781-90	15.4	42
290	Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1055-61	15.4	71
289	Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands. <i>British Journal of Haematology</i> , 2012 , 157, 747-52	4.5	18
288	Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A. <i>Haemophilia</i> , 2013 , 19, 106-12	3.3	14
287	Guidelines for the management of hemophilia. <i>Haemophilia</i> , 2013 , 19, e1-47	3.3	1227
286	Results from a large multinational clinical trial (guardianB) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. <i>Haemophilia</i> , 2013 , 19, 698-705	3.3	49
285	Results from a large multinational clinical trial (guardianI) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. <i>Haemophilia</i> , 2013 , 19, 691-7	3.3	70
284	Cytokine profile and FVIII inhibitors development in haemophilia A. <i>Haemophilia</i> , 2013 , 19, e139-42	3.3	13
283	Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors. <i>Haemophilia</i> , 2013 , 19, e151-66	3.3	6
282	Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice. 2013 , 5, 1684-97		49
281	Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors. 2013 , 132, 735-41		7
280	Factor VIII genotype characterization of haemophilia A affected patients with transient and permanent inhibitors: a comprehensive Argentine study of inhibitor risks. <i>Haemophilia</i> , 2013 , 19, 511-8	3.3	12
279	Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. <i>British Journal of Haematology</i> , 2013 , 160, 153-70	4.5	144

278	Significance of F8 missense mutations with respect to inhibitor formation. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 464-70	7	20
277	Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. 2013 , 131, e274-80		32
276	Nijmegen-Bethesda assay to measure factor VIII inhibitors. 2013 , 992, 321-33		23
275	Factor VIII inhibitors in hemophilia A: rationale and latest evidence. 2013 , 4, 59-72		123
274	Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 1300-9	15.4	43
273	Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors. <i>Haemophilia</i> , 2013 , 19, 322-9	3.3	
272	Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy. <i>British Journal of Haematology</i> , 2013 , 163, 385-92	4.5	12
271	Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice. 2013 , 288, 17051-6		21
270	Rituximab for treating inhibitors in children with hemophilia. 2013 ,		2
269	The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. <i>Blood</i> , 2013 , 121, 1446-54	2.2	79
268	Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. <i>Blood</i> , 2013 , 121, 1039-48	2.2	122
267	Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. <i>Blood</i> , 2013 , 122, 1954-62	2.2	150
266	Interventions for treating acute bleeding episodes in people with acquired hemophilia. 2013 ,		0
265	Hemophilia A and B. 2013 , 45-59		3
264	Acquired haemophilia A: a 2013 update. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 1114-20	7	85
263	Illustrated operative management of spontaneous bleeding and compartment syndrome of the lower extremity in a patient with acquired hemophilia A: a case report. 2014 , 8, 132		4
262	Inhibitor development and management in three non-severe haemophilia A patients with T295A variant. <i>Hamostaseologie</i> , 2014 , 34 Suppl 1, S9-12	1.9	2
261	Acquired Inhibitors to Factor VIII. 2014 , 85-94		0

260	Laboratory and Quality Control of Assays. 2014 , 309-317		
259	Standardization of Assays in Hemophilia. 2014 , 318-327		
258	A public health approach to the prevention of inhibitors in hemophilia. 2014 , 47, 669-73		7
257	Acquired hemophilia A: a frequently overlooked autoimmune hemorrhagic disorder. 2014 , 2014, 320674		30
256	Acquired hemophilia: a case report and review of the literature. <i>International Journal of Laboratory Hematology</i> , 2014 , 36, 398-407	2.5	22
255	Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors. <i>Haemophilia</i> , 2014 , 20, e7-14	3.3	13
254	Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. <i>Haemophilia</i> , 2014 , 20, 65-72	3.3	104
253	Laboratory testing for factor inhibitors. <i>Haemophilia</i> , 2014 , 20 Suppl 4, 94-8	3.3	18
252	Treatment Options for Acquired Hemophilia. 2014 , 93-111		
251	Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level). <i>Haemophilia</i> , 2014 , 20, 15-24	3.3	41
250	Pre-analytical heat treatment and a FVIII ELISA improve Factor VIII antibody detection in acquired haemophilia A. <i>British Journal of Haematology</i> , 2014 , 166, 953-6	4.5	18
249	National surveillance for hemophilia inhibitors in the United States: Summary report of an expert meeting. <i>American Journal of Hematology</i> , 2014 , 89, 621-5	7.1	4
248	The diagnosis and classification of autoimmune coagulopathy: an updated review. 2014 , 13, 587-90		11
247	The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients. 2014 , 30, 356-63		14
246	First molecular analysis of F8 gene in Algeria: identification of two novel mutations. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014 , 20, 741-8	3.3	1
245	Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A. <i>Haemophilia</i> , 2014 , 20, 624-9	3.3	6
244	A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. <i>Haemophilia</i> , 2014 , 20, 230-7	3.3	32
243	Interventions for treating acute bleeding episodes in people with acquired hemophilia A. 2014 , CD010761		3

242	Definitions in hemophilia: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 1935-9	15.4	354
241	Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry. <i>Haemophilia</i> , 2014 , 20, e280-6	3.3	40
240	Inhibitor eradication with rituximab in haemophilia: where do we stand?. <i>British Journal of Haematology</i> , 2014 , 165, 600-8	4.5	39
239	The association of HLA-DRB1 and HLA-DQB1 alleles with the development of factor VIII inhibitors in severe haemophilia A patients in India. 2014 , 84, 235-7		5
238	Factor VIII and IX Inhibitors in Hemophilia. 2014 , 82-92		
237	Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. <i>Blood</i> , 2014 , 124, 3880-6	2.2	142
236	Symptoms and diagnosis in hemophilia. 2014 , 22-33		
235	Updates from guardian's comprehensive registration programme. 2015 , 95 Suppl 81, 22-9		
234	Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients. <i>Haemophilia</i> , 2015 , 21, 784-90	3.3	33
233	Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®)) in previously treated patients with severe haemophilia A: interim results of the guardian(®)2 extension trial. <i>Haemophilia</i> , 2015 , 21, e436-9	3.3	10
232	Pearls and pitfalls in factor inhibitor assays. <i>International Journal of Laboratory Hematology</i> , 2015 , 37 Suppl 1, 52-60	2.5	16
231	Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. <i>Blood</i> , 2015 , 125, 1180-8	2.2	74
230	Factor VIII inhibitor: affinity is the clue. <i>Blood</i> , 2015 , 125, 1056-8	2.2	1
229	Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice. 2015 , 104, 2451-6		8
228	von Willebrand disease, molecular biology and diagnosis. 2015 , 83, 255-264		0
227	Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII. <i>Haemophilia</i> , 2015 , 21, e281-5	3.3	7
226	Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 1293-300	15.4	2
225	Inhibitors in nonsevere haemophilia A: outcome and eradication strategies. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 46-55	7	29

224	Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 804-11	7	13
223	Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?. <i>International Journal of Laboratory Hematology</i> , 2015 , 37, 125-32	2.5	2
222	Inhibitor development and mortality in non-severe hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 1217-25	15.4	41
221	Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A. 2015 , 56, 935-43		2
220	Improving the performance of factor VIII inhibitor tests in hemophilia A. 2015 , 136, 1047-8		4
219	Heat treatment of samples improve the performance of the Nijmegen-Bethesda assay in hemophilia A patients undergoing immune tolerance induction. 2015 , 136, 1280-4		10
218	Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A. <i>Haemophilia</i> , 2015 , 21, 343-50	3.3	39
217	Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein. 2015 , 66, 157-62		1
216	[Von Willebrand disease. Molecular biology and diagnosis]. 2015 , 83, 255-64		3
215	Hemophilia care in China: review of care for 417 hemophilia patients from 11 treatment centers in Shanxi Province. <i>Expert Review of Hematology</i> , 2015 , 8, 543-50	2.8	11
214	A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients. <i>Haemophilia</i> , 2015 , 21, 686-92	3.3	19
213	Rituximab for treating inhibitors in people with inherited severe hemophilia. 2015 , CD010810		2
212	Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. <i>Haemophilia</i> , 2015 , 21, 162-70	3.3	104
211	Real-life evidence in evaluating effectiveness of treatment in Haemophilia A with a recombinant FVIII concentrate: a non-interventional study in emerging countries. <i>Haemophilia</i> , 2015 , 21, e167-75	3.3	6
210	One-stage vs. chromogenic assays in haemophilia A. 2015 , 94 Suppl 77, 38-44		63
209	Inhibitors in haemophilia: what have we learned from registries? A systematic review. 2015 , 277, 1-15		20
208	Biomimetic biosensor to distinguish between inhibitory and non-inhibitory factor VIII antibodies. 2015 , 407, 5685-93		2
207	Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A. <i>Haemophilia</i> , 2015 , 21, 791-8	3.3	4

206	Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial. <i>Haemophilia</i> , 2015 , 21, 196-203	3.3	8
205	Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 47-53	15.4	25
204	The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 543-50	7	22
203	Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 729-37	7	16
202	Alkalemic conditions result in blood clotting in the circuit soon after initiating cardiopulmonary bypass. <i>Japanese Journal of Extra-corporeal Technology</i> , 2016 , 43, 346-351	0.1	
201	Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 659-68	7	40
200	Alloantibody developed in a factor XIII A subunit deficient patient during substitution therapy; characterization of the antibody. <i>Haemophilia</i> , 2016 , 22, 268-275	3.3	9
199	Rituximab as first-line therapy for acquired haemophilia A: a single-centre 10-year experience. <i>Haemophilia</i> , 2016 , 22, e338-41	3.3	4
198	Assessment of the frequency of regulatory T cells (CD4+CD25+CD127-) in children with hemophilia A: relation to factor VIII inhibitors and disease severity. <i>Blood Coagulation and Fibrinolysis</i> , 2016 , 27, 42-6 ¹		1
197	The thrombin generation assay distinguishes inhibitor from non-inhibitor patients with severe haemophilia A. <i>Haemophilia</i> , 2016 , 22, e286-91	3.3	5
196	Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A. <i>Haemophilia</i> , 2016 , 22, 374-80	3.3	26
195	Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 940-7	15.4	34
194	Interim results from a large multinational extension trial (guardian(II)) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A. <i>Haemophilia</i> , 2016 , 22, e445-9	3.3	6
193	Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm®). 2016 , 141, 69-76		46
192	Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. <i>Blood</i> , 2016 , 127, 1761-9	2.2	134
191	Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. <i>Blood</i> , 2016 , 128, 630-7	2.2	59
190	Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. <i>Haemophilia</i> , 2016 , 22, e259-66	3.3	20
189	Quality laboratory issues in bleeding disorders. <i>Haemophilia</i> , 2016 , 22 Suppl 5, 84-9	3.3	6

188	Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiiq) in children with severe haemophilia A: efficacy, safety and pharmacokinetics. <i>Haemophilia</i> , 2016 , 22, 232-239	3.3	34
187	First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. <i>Haemophilia</i> , 2016 , 22, 87-95	3.3	40
186	Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiiq) in adults with severe haemophilia A: efficacy and safety. <i>Haemophilia</i> , 2016 , 22, 225-231	3.3	30
185	A variation of the Nijmegen-Bethesda assay using heat or a novel heat/cold pretreatment for the detection of FIX inhibitors in the presence of residual FIX activity. <i>International Journal of Laboratory Hematology</i> , 2016 , 38, 639-647	2.5	4
184	Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 1931-1940	15.4	6
183	Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model. 2016 , 105, 3039-3045		6
182	Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile. <i>Haemophilia</i> , 2016 , 22, 308-317	3.3	24
181	Isotypic analysis of antibodies against activated Factor VII in patients with Factor VII deficiency using the x-MAP technology. 2016 , 141, 22-7		1
180	Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 1521-9	15.4	35
179	Neutralizing autoantibody against factor XIII A subunit resulted in severe bleeding diathesis with a fatal outcome - characterization of the antibody. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 1517-20 ⁴	15.4	3
178	Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents. <i>Haemophilia</i> , 2016 , 22, e292-300	3.3	8
177	B-cell memory against factor VIII. 2016 , 301, 49-58		9
176	Advances in the clinical management of inhibitors in hemophilia A and B. 2016 , 53, 20-7		21
175	Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors. 2016 , 169, 93-7		1
174	Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. <i>Haemophilia</i> , 2017 , 23, 67-76	3.3	24
173	Development of a novel automated screening method for detection of FVIII Inhibitors. <i>International Journal of Laboratory Hematology</i> , 2017 , 39, 185-190	2.5	1
172	Acquired haemophilia: Epidemiology, clinical presentation, diagnosis and treatment. 2017 , 148, 314-322		15
171	Acquired haemophilia: Epidemiology, clinical presentation, diagnosis and treatment. 2017 , 148, 314-322		2

170	Acquired hemophilia A: a review of recent data and new therapeutic options. 2017 , 22, 514-520		49
169	PK-guided personalized prophylaxis with Nuwiq (human-cl rhFVIII) in adults with severe haemophilia A. <i>Haemophilia</i> , 2017 , 23, 697-704	3.3	30
168	A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice. 2017 , 25, 1815-1830		38
167	Severe bleeding diatheses in an elderly patient with combined type autoantibody against factor XIII A subunit; novel approach to the diagnosis and classification of anti-factor XIII antibodies. <i>Haemophilia</i> , 2017 , 23, 590-597	3.3	2
166	Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A. 2017 , 8, 263-272		15
165	Clot waveform analysis using CS-2000i distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A. <i>Haemophilia</i> , 2017 , 23, e427-e435	3.3	21
164	IgG subclasses of FVIII inhibitors in an argentine cohort of severe hemophilia A patients: Analysis by flow cytometry. <i>International Journal of Laboratory Hematology</i> , 2017 , 39, 569-576	2.5	
163	Rituximab for treating inhibitors in people with inherited severe hemophilia. 2017 , 7, CD010810		2
162	Detection and Measurement of Factor Inhibitors. 2017 , 1646, 295-304		6
161	Człł: Wytyczne postępowania w hemofilii A i B powikłanej inhibitorem czynnika VIII i IX (2 wydanie). 2017 , 48, 137-159		0
160	Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 1971-1976	15.4	10
159	Assessment of Factor XIII. 2017 , 1646, 277-293		5
158	Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. <i>Haemophilia</i> , 2017 , 23, 33-41	3.3	14
157	Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics. <i>Haemophilia</i> , 2017 , 23, 292-299	3.3	1
156	Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 252-261	7	74
155	Investigation of Haemostasis. 2017 , 366-409		2
154	Auto- and alloantibodies against factor XIII: laboratory diagnosis and clinical consequences. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 822-832	15.4	11
153	Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels. <i>Haemophilia</i> , 2018 , 24, 487-491	3.3	13

152	F8 inversions of introns 22 and 1 confer a moderate risk of inhibitors in Mexican patients with severe hemophilia A. Concordance analysis and literature review. 2018 , 71, 45-52		4
151	Frequencies of intron 1 and 22 inversions of factor VIII gene: A first report in Afghan patients with severe haemophilia A. <i>Haemophilia</i> , 2018 , 24, e157-e160	3-3	4
150	Durable engraftment of genetically modified FVIII-secreting autologous bone marrow stromal cells in the intramedullary microenvironment. 2018 , 22, 3698-3702		5
149	Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen-Bethesda assay for factor VIII inhibitors. <i>Haemophilia</i> , 2018 , 24, e116-e119	3-3	3
148	Long-term tolerability, immunogenicity and efficacy of Nuwiq (human-cl rhFVIII) in children with severe haemophilia A. <i>Haemophilia</i> , 2018 , 24, 595-603	3-3	7
147	Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A. 2018 , 11, 283-288		0
146	Clinical trials and registries in haemophilia: Opponents or collaborators? Comparison of PUP data derived from different data sources. <i>Haemophilia</i> , 2018 , 24, 420-428	3-3	4
145	Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review. <i>Haemophilia</i> , 2018 , 24, 186-197	3-3	29
144	How I manage patients with inherited haemophilia A and B and factor inhibitors. <i>British Journal of Haematology</i> , 2018 , 180, 501-510	4-5	15
143	European principles of inhibitor management in patients with haemophilia. 2018 , 13, 66		17
142	Spectrum of Molecular Defects in 216 Chinese Families With Hemophilia A: Identification of Noninversion Mutation Hot Spots and 42 Novel Mutations. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018 , 24, 70-78	3-3	8
141	Acquired Factor VIII Inhibitor and Cardiopulmonary Bypass. 2018 , 32, 952-955		1
140	Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A. 2018 , 78, 1861-1872		20
139	Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm trials. <i>Haemophilia</i> , 2018 , 24, 911-920	3-3	9
138	Role of lupus anticoagulants in immediate acting inhibitor positivity in congenital haemophilia A patients. 2018 , 172, 29-35		0
137	Clinical and laboratory diagnosis of autoimmune factor V inhibitors: A single institutional experience. 2018 , 171, 14-21		4
136	Clinicopathological parameters influencing inhibitor development in patients with hemophilia A receiving on-demand therapy. 2018 , 9, 213-226		7
135	Ethnicity-specific impact of HLA I/II genotypes on the risk of inhibitor development: data from Korean patients with severe hemophilia A. 2018 , 97, 1695-1700		1

134	Optimization of pre-analytical heat treatment for inhibitor detection in haemophilia A. <i>International Journal of Laboratory Hematology</i> , 2018 , 40, 561-568	2.5	4
133	Risk factors for inhibitor development in severe hemophilia a. 2018 , 168, 20-27		42
132	Laboratory Evaluation of Hemostatic and Thrombotic Disorders. 2018 , 1922-1931		
131	Inhibitors in Hemophilias. 2018 , 2023-2033.e5		1
130	Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse model. 2018 , 548, 642-648		8
129	Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 1779-1788	15.4	6
128	Prevention and Management of Bleeding Episodes in Children with Hemophilia. 2018 , 20, 455-464		12
127	The role of the laboratory in diagnosis and management of inhibitory antibodies in haemophilia. <i>Haemophilia</i> , 2018 , 24 Suppl 6, 9-14	3.3	3
126	Reagent substitution in the chromogenic Bethesda assay for factor VIII inhibitors. <i>Haemophilia</i> , 2019 , 25, e342-e344	3.3	2
125	Low-dose immune tolerance induction for children with hemophilia A with poor-risk high-titer inhibitors: A pilot study in China. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019 , 3, 741-748	5.1	7
124	Polymorphisms in the cytotoxic T lymphocyte-associated protein-4 immune regulatory gene and their impact on inhibitor development in patients with hemophilia A. 2019 , 47, 4981-4992		3
123	Immunogenicity of Protein Pharmaceuticals. 2019 , 108, 1637-1654		42
122	Lupus anticoagulant-hypoprothrombinemia syndrome and similar diseases: experiences at a single center in Japan. <i>International Journal of Hematology</i> , 2019 , 110, 197-204	2.3	7
121	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019 , 3, 528-541	5.1	11
120	Dental management of patients with haemophilia in the era of recombinant treatments: increased efficacy and decreased clinical risk. 2019 , 12,		1
119	Perioperative Management of Hemophilia A Using Recombinant Factor VIII in Patients Undergoing Major or Minor Surgery. 2019 ,		
118	Compartment syndrome of the forearm with life-threatening bleeding after fasciotomy as the presenting sign of postpartum acquired hemophilia A: a case report. <i>Blood Coagulation and Fibrinolysis</i> , 2019 , 30, 120-126	1	2
117	Mixing-based inhibitor screening in haemophilia A: challenges in interpretation. <i>Blood Coagulation and Fibrinolysis</i> , 2019 , 30, 401-408	1	

116	Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse. 2019 , 20, 276		23
115	Involvement of antifactor VIII autoantibodies specificity in the outcome of inhibitor eradication therapies in acquired hemophilia a patients. <i>Blood Coagulation and Fibrinolysis</i> , 2019 , 30, 127-132	1	0
114	Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study. 2019 , 174, 84-87		4
113	Acquired Coagulation Disorders Caused by Inhibitors. 2019 , 80-92		1
112	Hemophilia A and Hemophilia B. 2019 , 39-58		2
111	Laboratory evaluation of hemostasis. 2020 , 765-792		0
110	Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1). <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 341-351	15.4	8
109	SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A. <i>Haemophilia</i> , 2020 , 26, 47-55	3.3	4
108	Clinical utility of sample preheat treatment in a modified Nijmegen-Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A single-centre four-year experience. <i>Haemophilia</i> , 2020 , 26, e300-e307	3.3	
107	Observational study of recombinant factor VIII-Fc, rFVIII-Fc, in hemophilia A. 2020 , 195, 51-54		3
106	Rituximab for treating inhibitors in people with inherited severe hemophilia. 2020 , 8, CD010810		1
105	An In Silico Exploration of the Factors That Affect the Precision of the Bethesda Assay. 2020 , 154, 671-682		
104	The Art of Detecting Antibodies against Factor VIII. <i>Hamostaseologie</i> , 2020 , 40, 485-490	1.9	0
103	ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1166-1172	7	1
102	Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 3222-3231	15.4	4
101	The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development. <i>Blood Advances</i> , 2020 , 4, 5785-5796	7.8	9
100	Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 1324-1330	5.1	
99	The rapid Bethesda assay is equivalent to the standard Bethesda assay for detection of factor IX inhibitors in patients with severe haemophilia B. <i>Haemophilia</i> , 2020 , 26, 735-740	3.3	

98	Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia A- A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2020 , 11, 563	8.4	2
97	Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. <i>British Journal of Haematology</i> , 2020 , 191, 347-362	4.5	5
96	Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18 Suppl 1, 5-14	15.4	7
95	Hemophilia management: Huge impact of a tiny difference. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 377-385	5.1	2
94	Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1242-1255	15.4	16
93	Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. <i>Haemophilia</i> , 2020 , 26, e168-e178	3.3	6
92	Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1065-1074	15.4	13
91	Identification of the Intron 22 and Intron 1 Inversions of the Factor VIII Gene in Iraqi Kurdish Patients With Hemophilia A. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020 , 26, 1076029619888293	3.3	2
90	Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A. <i>Haemophilia</i> , 2020 , 26, 478-486	3.3	1
89	Autoimmune factor XIII deficiency with unusual laboratory and clinical phenotype. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1330-1334	15.4	
88	Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. <i>Blood</i> , 2021 , 137, 1818-1827	2.2	13
87	Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study. <i>American Journal of Hematology</i> , 2021 , 96, 51-59	7.1	6
86	Optimization of the detection of inhibitory autoantibodies against the VWF-cleaving protease ADAMTS13 with an automated chemiluminescent ADAMTS13 activity immunoassay. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, 290-297	2.5	
85	Evaluation of anti-factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents. <i>Haemophilia</i> , 2021 , 27, e40-e50	3.3	
84	Inhibitory anti ADAMTS13 antibodies with a new rapid fully automated CLiA assay. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, 298-304	2.5	
83	Congenital Factor XIII Deficiency With the Presence of Inhibitor: A Case Study. <i>Journal of Pediatric Hematology/Oncology</i> , 2021 , 43, e99-e102	1.2	2
82	Acquired factor V inhibitor in the setting of coronavirus disease 2019 infection. <i>Blood Coagulation and Fibrinolysis</i> , 2021 , 32, 294-297	1	2
81	Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1400-1408	7	2

80	Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold?. <i>Expert Review of Hematology</i> , 2021 , 14, 263-270	2.8	1
79	Factor VIII/IX inhibitor testing practices in the United Kingdom: Results of a UKHCDO and UKNEQAS national survey. <i>Haemophilia</i> , 2021 , 27, 490-499	3.3	0
78	Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B. <i>Clinical and Translational Medicine</i> , 2021 , 11, e375	5.7	1
77	Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A. <i>Haemophilia</i> , 2021 , 27, 814-822	3.3	2
76	Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. <i>Lancet Haematology</i> , 2021 , 8, e492-e502	14.6	2
75	Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12562	5.1	0
74	Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low-dose secondary prophylaxis study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12552	5.1	1
73	Tolerogenic form of Factor VIII to prevent inhibitor development in the treatment of Hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2744-2750	15.4	0
72	Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins. <i>Scientific Reports</i> , 2021 , 11, 17853	4.9	0
71	Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: results from a single center in Japan. <i>International Journal of Hematology</i> , 2021 , 1	2.3	2
70	Acquired Hemophilia A. <i>Hematology/Oncology Clinics of North America</i> , 2021 , 35, 1131-1142	3.1	0
69	The incidence of inhibitors in hemophilia A and the induction of immune tolerance. <i>Advances in Experimental Medicine and Biology</i> , 2001 , 489, 89-97	3.6	2
68	Investigation of haemostasis. 2012 , 393-445		6
67	Coagulation and Fibrinolysis. 2011 , 785-800		4
66	Nonhemophilic Inhibitors of Coagulation. 2007 , 81-95		2
65	The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors Organization (UKHCDO). <i>British Journal of Haematology</i> , 2000 , 111, 78-90	4.5	107
64	Detection of all anti-factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assay. <i>Haemophilia</i> , 2001 , 7, 26-32	3.3	9
63	Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. <i>Haemophilia</i> , 2001 , 7, 33-8	3.3	39

62	Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay. <i>Haemophilia</i> , 2001 , 7, 13-9	3.3	15
61	Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A. <i>Haemophilia</i> , 2001 , 7, 364-8	3.3	24
60	Postpartum inhibitor to factor VIII: treatment with high-dose immunoglobulin and dexamethasone. <i>Haemophilia</i> , 2001 , 7, 422-7	3.3	13
59	Autoimmune factor VIII inhibitors. <i>Current Opinion in Hematology</i> , 1999 , 6, 314-22	3.3	25
58	Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 670-8	15.4	124
57	IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. <i>Journal of Clinical Investigation</i> , 2015 , 125, 3766-81	15.9	34
56	Mechanism and Kinetics of Factor VIII Inactivation: Study With an IgG4 Monoclonal Antibody Derived From a Hemophilia A Patient With Inhibitor. <i>Blood</i> , 1998 , 92, 496-506	2.2	3
55	Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonance. <i>PLoS ONE</i> , 2013 , 8, e61120	3.7	15
54	Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020 , 59, 365-371	5.9	4
53	Tolerating Factor VIII: Recent Progress. <i>Frontiers in Immunology</i> , 2019 , 10, 2991	8.4	19
52	Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients-A Known Issue of Unknown Origin. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 18,	4.6	2
51	A single-institution retrospective study of causes of prolonged prothrombin time and activated partial thromboplastin time in the outpatient setting. <i>International Journal of Laboratory Hematology</i> , 2021 ,	2.5	0
50	Erworbener Inhibitor gegen den Prothrombinkomplex: Differentialdiagnose einer verlängerten APTT bei einer Patientin mit einem niedrigmalignen B-Zell-NHL-(Marginalzonenlymphom). 2000 , 200-208		
49	Lithuanian Hemophilia A and B Register Comprising Phenotypic and Genotypic Data. 2001 , 132-143		
48	Hemophilia A and B. 2007 , 43-59		
47	B. 2007 , 165-222		
46	Methodological characteristics of Factor VIII : C inhibitor assays and the availability of inactivation treatment. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2008 , 19, 235-243	0	2
45	Elucidation of Gross Genomic Rearrangements Involving Large Deletions in the Clotting Factor VIII Gene. 2008 , 130-137		

44 Exploraci3 de la hemostasia. **2008**, 325-378

43 Methodological issue of assay for inhibitors to factor VIII/IX. *Japanese Journal of Thrombosis and Hemostasis*, **2010**, 21, 484-488

42 Inhibitordiagnostik. **2010**, 867-871

41 Inborn Defects of the Coagulative System. **2012**, 73-84

40 Hemostasis. **2012**, 2083-2128

39 Is blood accumulation under alkalemia related to platelet aggregation or thrombus formation during cardiopulmonary bypass surgery?. *Japanese Journal of Extra-corporeal Technology*, **2013**, 40, 1-6

0.1 1

38 B. **2013**, 231-286

37 Complications and life expectancy. **2014**, 90-100

36 Diagnostik, Klinik und Therapie der H3mophilie A und B. **1999**, 185-197

35 Alkalemic conditions result in blood clotting in the circuit soon after initiating cardiopulmonary bypass. *Japanese Journal of Extra-corporeal Technology*, **2016**, 43, 339-345

0.1

34 Bethesda-Einheiten. **2017**, 1-1

33 Bethesda-Einheiten. *Springer Reference Medizin*, **2019**, 431-431

0

32 Results of a prospective observation on the use of a coagulation factor concentrate VIII concentrate (Octanate®) for the induction of immunological tolerance in patients with an inhibitory form of hemophilia A. *Russian Journal of Pediatric Hematology and Oncology*, **2020**, 7, 54-63

0.3

31 Nonneutralizing FVIII-specific antibody signatures in patients with Hemophilia A and in healthy donors. *Blood Advances*, **2021**,

7.8 0

30 Combining factor VIII levels and thrombin/plasmin generation: a population pharmacokinetic-pharmacodynamic model for patients with hemophilia A. *British Journal of Clinical Pharmacology*, **2021**,

3.8 0

29 An Update on Laboratory Diagnostics in Haemophilia A and B. *Hamostaseologie*, **2022**,

1.9 0

28 Autoimmune (Acquired) Hemophilia: Updates in Diagnosis and Therapy. **2022**, 19,

0

27 Recombinant single-chain factor VIII in severe hemophilia: Long-term safety and efficacy in previously treated patients in the AFFINITY extension study.. *Research and Practice in Thrombosis and Haemostasis*, **2022**, 6, e12665

5.1 0

26	Advantages of external quality assessment-EQA programs.. <i>Haemophilia</i> , 2022 ,	3.3	○
25	A rare case of an anaphylactic reaction to plasma and recombinant blood coagulation factor VIII in a child with severe hemophilia A. <i>Oncogematologiya</i> , 2022 , 17, 36-42	0.3	
24	Data_Sheet_1.pdf. 2020 ,		
23	Inhibitors in Hemophilia A. 2022 , 19-28		
22	Inhibitors in Hemophilia B. 2022 , 45-51		
21	Advances in laboratory assessment of thrombosis and hemostasis.. <i>Blood Research</i> , 2022 , 57, 93-100	1.4	○
20	Longitudinal profiling of anti-factor VIII antibodies in Japanese patients with congenital hemophilia A during factor VIII replacement and immune-tolerance induction therapy.. <i>International Journal of Hematology</i> , 2022 ,	2.3	
19	Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice.. <i>Journal of Blood Medicine</i> , 2022 , 13, 255-265	2.3	○
18	Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway. <i>Frontiers in Immunology</i> , 2022 , 13,	8.4	○
17	Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study. <i>TH Open</i> , 2022 , 06, e124-e134	2.7	○
16	Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders. <i>Thrombosis and Haemostasis</i> ,	7	
15	Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A. <i>Haemophilia</i> ,	3.3	
14	Combined Immunosuppression for Acquired Hemophilia A: CyDRi is a Highly Effective Low Toxicity Regimen.		1
13	Methods for anti-factor VIII antibody levels in haemophilia A patients [Validation of a multiplex immunoassay and comparability with assays measuring non-neutralising and neutralising antibodies (inhibitors).		○
12	Stability of specimens for use in the Centers for Disease Control and Prevention assays for factor VIII and IX inhibitors. 2022 , 6,		○
11	Laparoscopic hepatectomy for hepatocellular carcinoma in a patient with congenital factor V deficiency: a case report. 2022 , 8,		○
10	A Diagnostic of Acquired Hemophilia Following PD1/PDL1 Inhibitors in Advanced Melanoma: The Experience of Two Patients and a Literature Review. 2022 , 12, 2559		○
9	F9 mutations causing deletion beyond serine protease domain confer higher risk for inhibitor development in hemophilia B.		○

8	Acquired Haemophilia A: A Review of What We Know. Volume 13, 691-710	0
7	Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice. 2022 , 12,	0
6	Acquired Haemophilia A in four north European countries: survey of 181 patients.	0
5	Hemophilia A: Emicizumab monitoring and impact on coagulation testing. 2023 ,	0
4	Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A. 2023 , 388, 310-318	1
3	The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice..	0
2	Early immune tolerance induction is a unique predictor of favorable outcomes in hemophilia A children with intron 22 inversion and high-responding inhibitors. 2023 ,	0
1	Low-dose immune tolerance induction therapy in severe hemophilia a children in China: Starting earlier resulted in better inhibitor eradication outcomes. 2023 , 225, 33-38	0